Semaglutide For Sale – Get Semaglutide to Achieve Your Goal

The molecular form of Semaglutide is as follows: C187H291N45O59. The unique numeric chemical compound identifier for Semaglutide is: 910463-68-2. Relative molecular weight: 4113.64 g/mol. Ozempic, Wegovy, GLP-1 and NN9535 mean the same thing as Semaglutide.

Although Semaglutide has become popular among millions of people worldwide, some people are prohibited from using the drug. The Food and Drug Administration amended the Ozempic registry in 2023 to include a warning about its use. This refers to the risk of gastrointestinal problems. For example, there is a chance of developing a condition where food or liquid is blocked in the colon and cannot leave the body. Medical products that stimulate insulin paired with Semaglutide may provoke a risk of hypoglycemia.

Black box warnings also apply to Semaglutide. These are special markings created by the Food and Drug Administration to inform end users about the possible drug risks. In the case of Semaglutide, there is the possibility of developing thyroid cancer. Studies with mice have shown the development of C-cell tumors. However, there is no direct evidence that the drug has the same negative effect on humans.

Semaglutide is based on GLP-1 receptors. These hormones are responsible for hunger and appetite triggering in the body. Thus, Semaglutide replaces these hormones and sends signals to the human brain that the feeling of hunger is absent. In addition, the drug normalizes sugar levels in the body, slows down gastric emptying, and makes the body burn more calories on its own.

Today, Semaglutide is used to treat two diseases including:

1. Obesity and overweight. Semaglutide has received special use among people who wish to get rid of obesity and overweight. We should note that the «overweight» category starts at a body mass index 27. The FDA organization approved Wegovy for weight management a few years ago. It is as if it tricks our brains that we don’t want to eat, thus suppressing our appetite. For beginners, starting with the lowest dose of 0.25 mg per week is recommended. Gradually, the dose can be increased. The maximum dose can be 2.4 mg of Semaglutide per week.
2. Type 2 diabetes. Semaglutide was originally developed and approved specifically for people with type 2 diabetes. The pharmaceutical companies Ozempic and Rybelsus are producing Semaglutide to treat type 2 diabetes. The dosage of Semaglutide for diabetes treatment is also similar to that of Wegovy. If you are just starting a course of treatment, you should stop at a dose of 0.25 mg and gradually increase the volume. 

Certainly, Semaglutide is often the main focus of research by different medical companies. Thanks to Semaglutide research, scientists are gradually finding better methods to fight obesity and treat type 2 diabetes.

STEP 1. Research on the effectiveness of Semaglutide among people with obesity and overweight

Sponsor Novo Nordisk in 2021 published the final results of a study involving more than 2,000 people who were 18 years of age or older. The main criterion for selecting participants was a body mass index above 27. The study lasted 68 weeks. During this time, participants took Semaglutide injections regularly every week. People were randomly divided into two groups – those taking Semaglutide and a placebo. 

The research’s conclusions were surprising. People who took regular injections of Semaglutide at a dosage of 2.4 mg per week managed to reduce their weight by an average of 15%. On the other hand, people who took a placebo achieved only a 2.4% reduction in body fat. The most popular side effects of Semaglutide include fatigue, nausea, dizziness, and vomiting. You can read the full report on the results of the STEP 1 study on the official website: https://clinicaltrials.gov/study/NCT03548935. 

STEP 2. Research on the effectiveness of Semaglutide among people who have type 2 diabetes

The second study involved 1,210 people who have type 2 diabetes and overweight problems. The participants were randomly divided into three groups: 1 mg dosage, 2.4 mg dosage, and taking a placebo. 

The results showed high efficacy of the drug in the group that took Semaglutide 2.4 mg dosage per week (about 9% weight loss). The placebo group showed a -3.4% weight loss result over the 68 weeks of treatment. Some adverse effects included: vomiting, diarrhea, and dizziness. The official source of the study: https://clinicaltrials.gov/study/NCT03552757. 

STEP 3. Research on the effectiveness of Semaglutide for weight loss with a healthy lifestyle

The next study’s participants were overweight people over 18 years of age who had no diabetes. The main phase traditionally lasted 68 weeks, during which 611 patients took Semaglutide and placebo paired with a healthy diet. Participants maintained a healthy lifestyle and exercised.

The patients who took Semaglutide weekly showed amazing results. This group of people managed to reduce their weight by 16%. Individuals who took a placebo achieved negligible results (5.7% weight loss). These results show that by adding diet and sport to the therapy, the results are significantly improved. You can read the full report at the official source: https://clinicaltrials.gov/study/NCT03611582. 

STEP 4. Research on comparing Semaglutide with a placebo for weight reduction

The aim of the fourth study was to compare the effect of Semaglutide with placebo on weight loss in obese people. The trial was divided into several stages and different groups of randomly selected people. The participants took Semaglutide for the first 20 weeks, and after that, they switched to a placebo.

As a result, after 68 weeks of taking Semaglutide injections and a placebo, the first group showed a 7.9% weight loss. From week 20 to 68, the patients took a placebo and showed a result of +6.9%. To find out more details about the 4 study, please visit the website: https://clinicaltrials.gov/study/NCT03548987. 

STEP 5. Research on the effectiveness and safety of Semaglutide for weight loss over two years

The latest study took two years, and the total number of participants was 304 overweight. Some took 2.4 mg of Semaglutide weekly, and some took a placebo.

108 weeks after the study started, the group of people who took Semaglutide distinguished themselves with excellent performance (16% weight loss). On the other hand, those who took a placebo were able to reduce their weight by only 2.6% after two years. More information on the official source: https://clinicaltrials.gov/study/NCT03693430.

Before the products hit the shelves of our store, each item undergoes thorough testing.